Trade-Ideas LLC identified Cytokinetics Inc. (NASDAQ:CYTK) as a “dead cat bounce” (down big yesterday but up big today) candidate. Cytokinetics, Inc. (NASDAQ:CYTK) stock opened at $9.38 in last session, and closed at $10.01, while the day range of Cytokinetics, Inc. (NASDAQ:CYTK) stock is $9.38 – $10.19. The stock showed a positive weekly performance of 9.76%.
Opexa Therapeutics Inc. (NASDAQ:OPXA) is a biopharmaceutical company. The Company is engaged in developing personalized cellular therapies with the potential to treat illnesses, including multiple sclerosis (MS). Opexa Therapeutics Inc. (NASDAQ:OPXA) stock opened at $1.68 in last session, and closed at $1.74 by gaining 3.57%. The 52 week range of $1.25 – $3.70. Company’s market capitalization is $25.62M.
On February 10, 2014, press release issued announcing, among other things, the appointment of Joseph DePinto as our Executive Vice President and Chief Commercial Officer and an update to the timeline to unblinding of the VALOR trial. A copy of the press release, entitled “Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Appoints Joseph I. DePinto as Chief Commercial Officer, Updates VALOR Timeline to Unblinding of Data” is attached hereto as Exhibit 99.1. Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) stock increased 4.35% and finished the last session at $5.04. The EPS of the stock remained -0.61. Company’s market capitalization is $260.56M.
Celldex Therapeutics, Inc. (NASDAQ:CLDX)announced that Anthony Marucci, President and Chief Executive Officer, and Tom Davis, M.D., Senior Vice President and Chief Medical Officer, presented a corporate overview at the 2014 Leerink Global Healthcare Conference on Wednesday, February 12, 2014. Celldex Therapeutics, Inc. (NASDAQ:CLDX) stock opened the session at $29.03, and closed the session at $31.56. The 52 week range of the Celldex Therapeutics, Inc. (NASDAQ:CLDX) stock remained $8.98 – $38.84 and the day range was $28.93 – $31.83.
Leave a Reply